Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

k related to the PROCAPS agreement which we terminated in 2012 and decreased litigation costs related to a settlement in 2011.

About Galectin TherapeuticsGalectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function.  We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development.  We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.  Additional information is available at www.galectintherapeutics.com.

Forward Looking StatementsThis press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others.  They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements.  Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others: incurrence of operating losses since our inception, uncertainty as to adequate financing of our operations, extensive and costly regulatory oversight that could restrict or prevent product commercialization, inability to achieve commercial product acceptance, inability to protect our intellectual property, dependence on strategic partnerships, product c
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 Xeno Diagnostics has again ... most recent COLA inspection. Xeno has met all ... healthcare accreditation organization. Accreditation is earned only by ... day-to-day operations, demonstrate continued accuracy in the performance ... laboratory survey. , While the Laboratory ...
(Date:12/17/2014)... 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a primary commercial focus on China ... Type C meeting with the U.S. Food and Drug ... in February 2015.  During this meeting the Company will ...
(Date:12/15/2014)... Dec. 15, 2014 Organovo Holdings, Inc. ... focused on delivering breakthrough 3D bioprinting technology,  today ... collaborators of its exVive3D TM Human Liver ... in full commercial release on November 18, has ... in several awards for innovation. Most ...
(Date:12/13/2014)... 2014 /CNW/ - MaRS and Virgin Unite Canada, the non-profit ... joined forces to support Canadian entrepreneurs tackling social and environmental ... was at the MaRS Centre to announce the new partnership, ... fund. This fund has $1 million in seed capital provided ... -based Mindset Social Innovation Foundation, founded by Alison Lawton ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3
... announces the pending release of its newest report, ... The 8.2 billion dollars appropriated to the ... Reinvestment Act is being earmarked for lab renovations, Challenge ... multiple public and non-profit institutions, all of which will ...
... XI,AN, China, Oct. 15 /PRNewswire-Asia-FirstCall/ -- ... leading non-state-owned,integrated energy company in China, today announced its selected ... The Company estimates sales to be ... $9.5 million, representing increases of 12.9% and 4.4%,respectively, compared to ...
... SIRO Clinpharm, a global Contract Research Organization (CRO) with its ... of its Clinical Trials Supplies facility in Mumbai, India. This ... biotech companies for storage and distribution of clinical trial supplies. ... , "We opened our clinical trials supplies warehouse in 2003 ...
Cached Biology Technology:BioInformatics, LLC New Report - The Market Outlook for Research Products in FY2010 2BioInformatics, LLC New Report - The Market Outlook for Research Products in FY2010 3China Integrated Energy, Inc. Announces Preliminary Third Quarter Financial Results and Increases Full Year Guidance 2SIRO Clinpharm Strengthens its Clinical Trials Supplies Service Offering in India 2
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the ... APAC Region 2015-2019"  report to their offering. ... market is advances in technology. With continuous advances ... solutions to the latest standard that meets the ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... month,s special issue of Physics World is devoted ... of how pond skaters effortlessly skip across water leaving nothing ... Ornes writes, our current understanding of the mechanisms adopted by ... Hu, who as a mathematics graduate from the Massachusetts Institute ...
... evolution or mentoring students, SMU Earth Sciences Professor Louis ... teachers. The 7,200-member Science Teachers Association of Texas, ... advance quality science education. A world-recognized vertebrate paleontologist, ... Skoog Cup. Jacobs is a professor in SMU,s Roy ...
... 1000 Genomes Project today presents a map of normal human ... code to major alterations in our chromosomes. In a DNA ... genomes of 1092 healthy people from Europe, the Americas and ... other. Their results, published in Nature , open new ...
Cached Biology News:Pond skating insects reveal water-walking secrets 2SMU professor Louis Jacobs honored with prestigious award from Texas science teachers 2SMU professor Louis Jacobs honored with prestigious award from Texas science teachers 3SMU professor Louis Jacobs honored with prestigious award from Texas science teachers 4Spot the difference 2
Mouse GM CSF Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient...
Immunogen: Recombinant rabbit tryptophan hydroxylase, isolated as inclusion bodies from E. coli and purified by preparative SDS-PAGE. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... GeneBLAzer cell-based assays utilize the ... of the negatively charged fluorescent beta-lactamase ... esters readily enter the cell, where ... converts them into their negatively charged ...
Biology Products: